The impact of glucose and sodium lowering therapies on heart and kidney disease
The University of Western Australia
$20,000
Coordinating Principal Investigator: Dr Vance Matthews
Co-Investigators: Dr Lakshini Herat, Professor Markus Schlaich, Mrs Jennifer Matthews,
This research project aims to explore a new approach for treating hypertension, a widespread and serious health issue. The project focuses on a protein called sodium and glucose co-transporter 1 (SGLT-1) and its potential role in regulating blood pressure. By inhibiting SGLT-1, the researchers believe they can improve hypertension controlled by the fight or flight response.
The innovative pre-clinical studies, if successful, will provide a crucial foundation for future research and offer a framework for analysing biomarkers. This could pave the way for more precise and effective treatments for hypertensive patients. The study follows a 'bench-to-bedside' model, meaning insights gained from basic science can directly benefit clinicians and researchers globally, enhancing health outcomes for hypertensive patients.
Cardiovascular disease, especially hypertension, is a major global health concern. The research focuses on the kidneys' role in glucose reabsorption, particularly through SGLT1 and SGLT2 receptors. Existing medications that target SGLT2 have shown promise in reducing cardiovascular risk. The researchers aim to extend this understanding by investigating the impact of inhibiting SGLT-1, especially in the context of neurogenic hypertension.
The study is unique, being the first to examine the effects of SGLT-1 inhibition on neurogenic hypertension using well-established mouse models. The hypothesis is that targeting SGLT-1 could be a novel strategy to mitigate the development and progression of neurogenic hypertension and related renal complications. If successful, this approach could lead to better, more tailored treatment options with fewer side effects and increased cost-effectiveness, ultimately improving the lives of hypertensive patients.